RU2013127611A - Модуляторы глюкагонового рецептора - Google Patents
Модуляторы глюкагонового рецептора Download PDFInfo
- Publication number
- RU2013127611A RU2013127611A RU2013127611/04A RU2013127611A RU2013127611A RU 2013127611 A RU2013127611 A RU 2013127611A RU 2013127611/04 A RU2013127611/04 A RU 2013127611/04A RU 2013127611 A RU2013127611 A RU 2013127611A RU 2013127611 A RU2013127611 A RU 2013127611A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
- C07D241/34—(Amino-pyrazine carbonamido) guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Соединение Формулы Iили его фармацевтически приемлемая соль, гдеRпредставляет собой фенил-замещенный гало или трифторметилом;или 6-членную гетероарильную группу, которая, необязательно, конденсирована с (С-С)циклоалкилом, фенилом или 5-6 членным гетероарилом, и где необязательно конденсированная 6-членная гетероарильная группа, необязательно, замещена одним - четырьмя заместителями, где каждый независимо выбирают из гало, -S(O)-(С)алкила, гидрокси, -C(O)NRR, циано, (С-С)алкила, необязательно, замещенного одним - тремя фторами, или (С-С)алкокси, необязательно, замещенного одним - тремя фторами;Rи Rкаждый независимо представляет собой Н или (С-С)алкил;Rпредставляет собой Н;Rпредставляет собой -(СН)СОН;А, А, Аи Акаждый независимо представляет собой CRили N, при условии, что один или два из А, А, Аи Апредставляют собой N и при дополнительном условии, что Аи Аоба не являются N;Rв каждом случае, независимо, представляет собой Н, гало, циано, (С-С)алкил, необязательно, замещенный одним - тремя фторами, или (С-С)алкокси, необязательно замещенный одним - тремя фторами;L представляет собой -CH(R)-X-;X представляет собой NH;Rпредставляет собой (С-С)алкил, который необязательно замещен одним - тремя фторами, гидрокси или метокси; (С-С)циклоалкил, который необязательно замещен одним - двумя (С-С)алкилами, которые необязательно замещены одним - тремя фторами или одним - двумя (С-С)алкилами, и где один - два углерода (С-С)циклоалкила могут быть заменены NH, N(С-С)алкилом, О или S; или (С-С)циклоалкил-(С-С)алкил, где (С-С)циклоалкильная группа упомянутого (С-С)циклоалкил-(С-С)алкила необязательно замещена одним - двумя (С-С)алкилами, которые, необязательно, замещены одним - тр�
Claims (10)
1. Соединение Формулы I
или его фармацевтически приемлемая соль, где
R1 представляет собой фенил-замещенный гало или трифторметилом;
или 6-членную гетероарильную группу, которая, необязательно, конденсирована с (С4-С7)циклоалкилом, фенилом или 5-6 членным гетероарилом, и где необязательно конденсированная 6-членная гетероарильная группа, необязательно, замещена одним - четырьмя заместителями, где каждый независимо выбирают из гало, -S(O)2-(С1-3)алкила, гидрокси, -C(O)NRaRb, циано, (С1-С6)алкила, необязательно, замещенного одним - тремя фторами, или (С1-С6)алкокси, необязательно, замещенного одним - тремя фторами;
Ra и Rb каждый независимо представляет собой Н или (С1-С3)алкил;
R2 представляет собой Н;
R3 представляет собой -(СН2)2СО2Н;
А1, А2, А3 и А4 каждый независимо представляет собой CR4 или N, при условии, что один или два из А1, А2, А3 и А4 представляют собой N и при дополнительном условии, что А2 и А3 оба не являются N;
R4 в каждом случае, независимо, представляет собой Н, гало, циано, (С1-С3)алкил, необязательно, замещенный одним - тремя фторами, или (С1-С3)алкокси, необязательно замещенный одним - тремя фторами;
L представляет собой -CH(R5)-X-;
X представляет собой NH;
R5 представляет собой (С1-С6)алкил, который необязательно замещен одним - тремя фторами, гидрокси или метокси; (С3-С7)циклоалкил, который необязательно замещен одним - двумя (С1-С3)алкилами, которые необязательно замещены одним - тремя фторами или одним - двумя (С1-С3)алкилами, и где один - два углерода (С3-С7)циклоалкила могут быть заменены NH, N(С1-С3)алкилом, О или S; или (С3-С7)циклоалкил-(С1-С6)алкил, где (С3-С7)циклоалкильная группа упомянутого (С3-С7)циклоалкил-(С1-С6)алкила необязательно замещена одним - двумя (С1-С3)алкилами, которые, необязательно, замещены одним - тремя фторами;
В1, В2, В3 и В4 каждый независимо представляет собой CR6 или N, при условии, что не больше, чем два из В1, В2, В3 и В4 представляют собой N; и
R6 в каждом случае, независимо представляет собой Н, гало, (С1-С3)алкил, необязательно замещенный одним - тремя фторами, или (С1-С3)алкокси, необязательно замещенный одним - тремя фторами.
2. Соединение по п. 1 или его фармацевтически приемлемая соль, где R5 представляет собой этил, пропил, изопропил, т-бутил, пентил, неопентил, циклопропил, циклобутил, циклопентил, циклогексил или циклопропилметил, где каждый необязательно замещен 1-3 фторами и, где каждый упомянутый циклопропил, циклобутил, циклопентил, циклогексил, необязательно замещен 1-2 метилами.
3. Соединение по п. 1 или его фармацевтически приемлемая соль, где R1 представляет собой 4-фторметилфенил или 4-хлорфенил; и R4 и R6 в каждом случае представляет собой Н.
4. Соединение по п. 3 или его фармацевтически приемлемая соль, где В1 представляет собой N и В2, В3 и В4 каждый представляет собой CR6; В2 представляет собой N и В1, В3 и В4 каждый представляет собой CR6; В1 и В4 каждый представляет собой N и В2 и В3 каждый представляет собой CR6; В2 и В3 каждый представляет собой N и В1 и В4 каждый представляет собой CR6; или В1 и В3 каждый представляет собой N и В2 и В4 каждый представляет собой CR6.
5. Соединение по п. 1 или его фармацевтически приемлемая соль, где А1 представляет собой N и А2, А3 и А4 каждый представляет собой CR4; А2 представляет собой N и А1, А3 и А4 каждый представляет собой CR4; А1 и А4 каждый представляет собой N и А2 и А3 каждый представляет собой CR4; или А1 и А3 каждый представляет собой N и А2 и А4 каждый представляет собой CR4.
6. 3-[(6-{(S)-3-метил-1-[2-(4-трифторметилфенил)пиримидин-5-iл]бутиламино}пиридин-3-карбонил)амино]пропановая кислота или его фармацевтически приемлемая соль.
7. Фармацевтическая композиция, содержащая (i) соединение по п. 1 или его фармацевтически приемлемую соль и (ii) фармацевтически приемлемый эксципиент, разбавитель или носитель.
8. Композиция по п. 7, где упомянутое соединение или упомянутая его фармацевтически приемлемая соль, присутствуют в терапевтически эффективном количестве.
9. Применение соединения по п. 1 или его фармацевтически приемлемой соли при изготовлении медикамента для лечения или отсрочки развития или появления диабета Типа 2 и диабетзависимых расстройств.
10. Применение соединения по п. 1 или его фармацевтически приемлемой соли при изготовлении медикамента для лечения заболевания, состояния или расстройства, модулируемого деактивацией рецептора глюкагона.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426600P | 2010-12-23 | 2010-12-23 | |
US61/426,600 | 2010-12-23 | ||
US201161562008P | 2011-11-21 | 2011-11-21 | |
US61/562,008 | 2011-11-21 | ||
PCT/IB2011/055588 WO2012085745A1 (en) | 2010-12-23 | 2011-12-09 | Glucagon receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013127611A true RU2013127611A (ru) | 2015-01-27 |
Family
ID=45464650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013127611/04A RU2013127611A (ru) | 2010-12-23 | 2011-12-09 | Модуляторы глюкагонового рецептора |
Country Status (17)
Country | Link |
---|---|
US (4) | US8809342B2 (ru) |
EP (1) | EP2655331A1 (ru) |
JP (1) | JP5694561B2 (ru) |
KR (1) | KR101506829B1 (ru) |
CN (1) | CN103261165B (ru) |
AR (1) | AR084579A1 (ru) |
AU (1) | AU2011346670B2 (ru) |
BR (1) | BR112013016033A2 (ru) |
CA (1) | CA2822017C (ru) |
MX (1) | MX2013006768A (ru) |
NZ (1) | NZ611529A (ru) |
RU (1) | RU2013127611A (ru) |
SG (1) | SG191040A1 (ru) |
TW (1) | TWI429630B (ru) |
UY (1) | UY33824A (ru) |
WO (1) | WO2012085745A1 (ru) |
ZA (1) | ZA201303950B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
EP2655331A1 (en) * | 2010-12-23 | 2013-10-30 | Pfizer Inc | Glucagon receptor modulators |
CN104350040B (zh) | 2012-03-29 | 2016-06-01 | 武田药品工业株式会社 | 芳环化合物 |
AU2014254262B2 (en) | 2013-04-15 | 2018-08-23 | Fmc Corporation | Fungicidal carboxamides |
HUE039687T2 (hu) * | 2013-10-17 | 2019-01-28 | Blueprint Medicines Corp | Kompozíciók, amelyek alkalmazhatók KIT-tel kapcsolatos rendellenességek kezelésében való alkalmazásra |
CN115052855A (zh) * | 2020-03-06 | 2022-09-13 | 昊运股份有限公司 | 酰胺化合物的制备方法、其晶型及其盐类 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320825A (en) | 1991-05-01 | 1994-06-14 | Trustees Of The University Of Pennsylvania | Serotonin reuptake inhibitors for S.P.E.C.T. imaging |
WO1994014427A2 (en) | 1992-12-23 | 1994-07-07 | Zymogenetics, Inc. | Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation |
EP0617001B1 (en) | 1993-03-19 | 2000-01-26 | Merck & Co. Inc. | Phenoxyphenylacetic acid derivatives |
GB9408185D0 (en) | 1994-04-25 | 1994-06-15 | Fujisawa Pharmaceutical Co | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
DE4426346A1 (de) | 1994-07-25 | 1996-02-01 | Basf Ag | Herbizide Pyrazinderivate |
GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
WO1996009818A1 (en) | 1994-09-27 | 1996-04-04 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
US5837719A (en) | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
JPH11514651A (ja) | 1995-10-31 | 1999-12-14 | メルク エンド カンパニー インコーポレーテッド | 置換ピリジルピロール、前記化合物を含む組成物及び使用方法 |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US5776954A (en) | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
CA2271893A1 (en) | 1996-11-20 | 1998-05-28 | Linda L. Chang | Triaryl substituted imidazoles as glucagon antagonists |
US5880139A (en) | 1996-11-20 | 1999-03-09 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
EP0948496A2 (en) | 1996-12-05 | 1999-10-13 | Amgen inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
WO1998024782A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
CN1245486A (zh) | 1996-12-11 | 2000-02-23 | Basf公司 | 用作钙蛋白酶抑制剂的酮苯甲酰胺 |
JPH10259176A (ja) | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
KR20010033241A (ko) | 1997-12-19 | 2001-04-25 | 스티븐 엠. 오드레 | 치환된 피리딘 및 피리다진 화합물과 그것의 제약학적 용도 |
PT1177176E (pt) | 1999-04-28 | 2006-08-31 | Aventis Pharma Gmbh | Derivados de acidos triarilicos como ligandos de receptores ppar. |
DK1177187T3 (da) | 1999-04-28 | 2007-10-15 | Sanofi Aventis Deutschland | Diarylsyrederivater som PPAR-receptorligander |
PL352367A1 (en) | 1999-05-17 | 2003-08-25 | Novo Nordisk As | Glucagon antagonists/inverse agonists |
HUP0301501A2 (hu) | 2000-06-23 | 2003-08-28 | Novo Nordisk A/S | Glükagon antaagonista/inverz agonista vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása gyógyászati készítmények előállítására |
AU2002223502A1 (en) | 2000-11-17 | 2002-05-27 | Novo-Nordisk A/S | Glucagon antagonist/inverse agonist |
US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
HUP0303376A3 (en) | 2001-02-28 | 2007-08-28 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
WO2003047626A1 (en) | 2001-12-03 | 2003-06-12 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
JP2005511683A (ja) | 2001-12-03 | 2005-04-28 | ノボ ノルディスク アクティーゼルスカブ | 新規なグルカゴンアンタゴニスト |
WO2003051357A1 (en) | 2001-12-19 | 2003-06-26 | Novo Nordisk A/S | Glucagon receptor antagonists/inverse agonists |
AU2002347022A1 (en) | 2001-12-20 | 2003-07-09 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
PL370989A1 (en) | 2001-12-21 | 2005-06-13 | Novo Nordisk A/S | Amide derivatives as gk activators |
MXPA04007474A (es) | 2002-02-01 | 2004-11-10 | Dainippon Pharmaceutical Co | Hidrazidas del acido 2-furancarboxilico y composiciones farmaceuticas que la contienen. |
EP1487843A4 (en) | 2002-03-20 | 2010-03-10 | Metabolex Inc | SUBSTITUTED PHENYLACETIC ACIDS |
WO2003087044A2 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
AU2003233780A1 (en) | 2002-06-27 | 2004-01-19 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
PL215132B1 (pl) | 2002-06-27 | 2013-10-31 | Novo Nordisk As | Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca |
WO2004024066A2 (en) | 2002-09-12 | 2004-03-25 | Merck & Co., Inc. | Method of treating diabetes and related conditions |
US7196106B2 (en) | 2002-11-05 | 2007-03-27 | Merck & Co., Inc | Cyanothiophene derivatives, compositions containing such compounds and methods of use |
US20040097557A1 (en) | 2002-11-13 | 2004-05-20 | Duffy Joseph L. | Cyanothiophene derivatives, compositions containing such compounds and methods of use |
CA2508581A1 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
AU2003291959A1 (en) | 2002-12-20 | 2004-07-14 | Novo Nordisk A/S | Novel glucagon antagonists |
US20040209928A1 (en) | 2002-12-30 | 2004-10-21 | Ravi Kurukulasuriya | Glucagon receptor antagonists/inverse agonists |
US7151114B2 (en) | 2003-01-09 | 2006-12-19 | Boehringer Ingelheim International Gmbh | Use of substituted 2-phenylbenzimidazoles as medicaments |
DE10300398A1 (de) | 2003-01-09 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel |
WO2004063147A1 (en) | 2003-01-10 | 2004-07-29 | Novo Nordisk A/S | Salts and solvates of glucagon antagonists |
DE602004030318D1 (de) | 2003-01-27 | 2011-01-13 | Merck Sharp & Dohme | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren |
MXPA05010937A (es) | 2003-04-14 | 2005-11-25 | Inst For Pharm Discovery Inc | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. |
US7138529B2 (en) | 2003-04-16 | 2006-11-21 | Hoffmann-La Roche Inc. | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
JP2006525365A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | フェニル置換カルボン酸 |
WO2004100875A2 (en) | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
US7355049B2 (en) | 2003-06-24 | 2008-04-08 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator |
JP4412098B2 (ja) | 2003-07-31 | 2010-02-10 | Jfeスチール株式会社 | 溶接熱影響部靭性に優れた低降伏比高強度鋼板及びその製造方法 |
WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
JP2007514794A (ja) | 2003-12-19 | 2007-06-07 | メルク エンド カムパニー インコーポレーテッド | 環式グアニジン、そのような化合物を含む組成、及び使用方法 |
WO2005058845A2 (en) | 2003-12-19 | 2005-06-30 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
EA010888B1 (ru) | 2004-05-25 | 2008-12-30 | Пфайзер Продактс, Инк. | Тетраазабензо[е]азуленовые производные и их аналоги |
ES2428538T3 (es) | 2004-05-28 | 2013-11-08 | Eli Lilly And Company | Antagonistas del receptor de glucagón, preparación y usos terapéuticos |
ES2306165T3 (es) | 2004-06-04 | 2008-11-01 | MERCK & CO., INC. | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso. |
CA2569459C (en) * | 2004-06-14 | 2013-01-29 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
AU2005272043B2 (en) | 2004-07-07 | 2010-07-29 | Merck Sharp & Dohme Corp. | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
EP1773330B1 (en) | 2004-07-22 | 2010-05-26 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
DE102004051188A1 (de) | 2004-10-21 | 2006-04-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cyanothiophene, deren Herstellung und deren Verwendung als Arzneimittel |
US7524870B2 (en) | 2004-12-03 | 2009-04-28 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators |
US20060122236A1 (en) * | 2004-12-06 | 2006-06-08 | Wood Michael R | Substituted biaryl-carboxylate derivatives |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
ES2332470T3 (es) | 2005-02-11 | 2010-02-05 | Eli Lilly And Company | Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos. |
CN101146762A (zh) | 2005-03-21 | 2008-03-19 | 默克公司 | 取代的芳基和杂芳基衍生物 |
CA2600833A1 (en) | 2005-03-30 | 2006-10-05 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US7709658B2 (en) | 2005-07-26 | 2010-05-04 | Merck Sharp & Dohme Corp. | Process for synthesizing a substituted pyrazole |
US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
RU2440123C2 (ru) | 2005-10-06 | 2012-01-20 | Проби Аб | Применение lactobacillus для лечения вирусных инфекций |
TW200745031A (en) | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
JP5199108B2 (ja) | 2005-11-14 | 2013-05-15 | ユニヴァーシティー オブ サザン カリフォルニア | インテグリン結合小分子 |
AU2006340002B2 (en) | 2005-11-17 | 2011-12-22 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
ES2393757T3 (es) | 2005-11-17 | 2012-12-27 | Eli Lilly & Company | Antagonistas de receptor de glucagón, preparación y usos terapéuticos |
AU2006341392B2 (en) | 2005-11-18 | 2012-05-17 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
US8691856B2 (en) * | 2005-11-22 | 2014-04-08 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
SI1957484T1 (sl) | 2005-11-23 | 2010-07-30 | Lilly Co Eli | Antagonisti glukagonskega receptorja, priprava in terapevtske uporabe |
WO2007072179A2 (en) | 2005-12-19 | 2007-06-28 | Methylgene, Inc. | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
TW200806611A (en) | 2006-02-09 | 2008-02-01 | Daiichi Seiyaku Co | Novel amidopropionic acid derivatives and medicine containing the same |
AU2007229850A1 (en) | 2006-03-23 | 2007-10-04 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
WO2007136577A2 (en) | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
CN107669669A (zh) | 2007-02-09 | 2018-02-09 | 症变治疗公司 | 新颖的胰高血糖素受体拮抗剂 |
JP2009040702A (ja) | 2007-08-07 | 2009-02-26 | Daiichi Sankyo Co Ltd | 新規アミドプロピオン酸誘導体を含有する医薬組成物 |
WO2009035558A1 (en) | 2007-09-12 | 2009-03-19 | Merck & Co., Inc. | Process for the production of a crystalline glucagon receptor antagonist compound |
WO2009057784A1 (ja) * | 2007-11-01 | 2009-05-07 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
KR101277560B1 (ko) | 2007-12-11 | 2013-06-25 | 카딜라 핼쓰캐어 리미티드 | 글루카곤 안타고니스트 활성 및 glp-1 아고니스트 활성의 펩티드 유사체 |
US8436043B2 (en) | 2008-03-05 | 2013-05-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JP5382952B2 (ja) | 2008-03-07 | 2014-01-08 | トランス テック ファーマ,インコーポレイテッド | 糖尿病の治療のためのオキサジアゾアントラセン化合物 |
CA2724294A1 (en) | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
WO2010019828A1 (en) * | 2008-08-13 | 2010-02-18 | Metabasis Therapeutics, Inc. | Glucagon receptor antagonists |
MX2011001708A (es) | 2008-08-13 | 2011-04-26 | Metabasis Therapeutics Inc | Antagonistas de glucagon. |
EP2346830B1 (en) | 2008-09-15 | 2015-05-13 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
CA2738663A1 (en) | 2008-10-03 | 2010-04-08 | Schering Corporation | Spiro-imidazolone derivatives as glucagon receptor antagonists |
WO2010071750A1 (en) | 2008-12-19 | 2010-06-24 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
WO2010080971A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Crystalline polymorphic forms of an antidiabetic compound |
US20110281795A1 (en) | 2009-01-28 | 2011-11-17 | Songnian Lin | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
WO2010098948A1 (en) | 2009-02-13 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use |
US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
TWI491393B (zh) | 2009-05-14 | 2015-07-11 | Sumitomo Dainippon Pharma Co Ltd | 3- (4-aminophenyl) -2-furancarboxylic acid derivatives and pharmaceutically acceptable salts thereof |
WO2010144664A1 (en) | 2009-06-12 | 2010-12-16 | Schering Corporation | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | 3−(4−置換アルキル−フェニル)−2−フランカルボン酸誘導体およびその薬学的に許容される塩 |
WO2011027849A1 (ja) | 2009-09-04 | 2011-03-10 | 武田薬品工業株式会社 | 複素環化合物 |
WO2011037815A1 (en) | 2009-09-22 | 2011-03-31 | Schering Corporation | Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
CA2794003A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
CA2793949A1 (en) | 2010-03-26 | 2011-09-29 | Merck Sharp & Dohme Corp. | Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use |
CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
EP2655331A1 (en) * | 2010-12-23 | 2013-10-30 | Pfizer Inc | Glucagon receptor modulators |
-
2011
- 2011-12-09 EP EP11805952.6A patent/EP2655331A1/en not_active Withdrawn
- 2011-12-09 JP JP2013545549A patent/JP5694561B2/ja not_active Expired - Fee Related
- 2011-12-09 CN CN201180061388.0A patent/CN103261165B/zh not_active Expired - Fee Related
- 2011-12-09 KR KR1020137016206A patent/KR101506829B1/ko not_active IP Right Cessation
- 2011-12-09 AU AU2011346670A patent/AU2011346670B2/en not_active Ceased
- 2011-12-09 BR BR112013016033A patent/BR112013016033A2/pt not_active IP Right Cessation
- 2011-12-09 CA CA2822017A patent/CA2822017C/en not_active Expired - Fee Related
- 2011-12-09 MX MX2013006768A patent/MX2013006768A/es active IP Right Grant
- 2011-12-09 RU RU2013127611/04A patent/RU2013127611A/ru not_active Application Discontinuation
- 2011-12-09 WO PCT/IB2011/055588 patent/WO2012085745A1/en active Application Filing
- 2011-12-09 NZ NZ611529A patent/NZ611529A/en not_active IP Right Cessation
- 2011-12-09 SG SG2013043732A patent/SG191040A1/en unknown
- 2011-12-21 UY UY0001033824A patent/UY33824A/es not_active Application Discontinuation
- 2011-12-22 TW TW100148111A patent/TWI429630B/zh not_active IP Right Cessation
- 2011-12-22 AR ARP110104917A patent/AR084579A1/es unknown
- 2011-12-22 US US13/334,202 patent/US8809342B2/en not_active Expired - Fee Related
-
2013
- 2013-05-30 ZA ZA2013/03950A patent/ZA201303950B/en unknown
-
2014
- 2014-07-18 US US14/334,718 patent/US8933104B2/en not_active Expired - Fee Related
- 2014-12-05 US US14/561,879 patent/US9056834B2/en not_active Expired - Fee Related
-
2015
- 2015-06-05 US US14/731,632 patent/US20150266861A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2012085745A1 (en) | 2012-06-28 |
US8809342B2 (en) | 2014-08-19 |
US20150266861A1 (en) | 2015-09-24 |
EP2655331A1 (en) | 2013-10-30 |
SG191040A1 (en) | 2013-08-30 |
US8933104B2 (en) | 2015-01-13 |
CN103261165B (zh) | 2015-08-26 |
BR112013016033A2 (pt) | 2018-06-05 |
UY33824A (es) | 2012-07-31 |
CA2822017C (en) | 2015-04-07 |
JP2014500306A (ja) | 2014-01-09 |
AR084579A1 (es) | 2013-05-29 |
MX2013006768A (es) | 2013-07-22 |
AU2011346670A1 (en) | 2013-07-25 |
AU2011346670B2 (en) | 2015-05-07 |
TW201302706A (zh) | 2013-01-16 |
TWI429630B (zh) | 2014-03-11 |
CN103261165A (zh) | 2013-08-21 |
KR20130087588A (ko) | 2013-08-06 |
US20140329862A1 (en) | 2014-11-06 |
CA2822017A1 (en) | 2012-06-28 |
JP5694561B2 (ja) | 2015-04-01 |
US20150094338A1 (en) | 2015-04-02 |
US9056834B2 (en) | 2015-06-16 |
NZ611529A (en) | 2015-06-26 |
KR101506829B1 (ko) | 2015-03-30 |
US20120165343A1 (en) | 2012-06-28 |
ZA201303950B (en) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013127611A (ru) | Модуляторы глюкагонового рецептора | |
RU2460730C2 (ru) | Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли | |
RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
RU2013137452A (ru) | Композиции, содержащие расщепляемое ферментами пролекарство оксикодона | |
RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
EA201500266A1 (ru) | Ингибиторы репликации вирусов гриппа | |
JP2011509309A5 (ru) | ||
RU2011105768A (ru) | Производные пиперидина в качестве ингибиторов jakз | |
AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
RU2013148146A (ru) | Производные адамантила | |
JP2015524472A5 (ru) | ||
RU2015120478A (ru) | Пери-карбинолы | |
RU2012158142A (ru) | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации | |
RU2013140169A (ru) | Противоопухолевое терапевтическое средство | |
JP2017508795A5 (ru) | ||
JP2016531126A5 (ru) | ||
RU2017110211A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
RU2013116801A (ru) | Ингибиторы notum пектинацетилэстеразы и способы их применения | |
JP2017508794A5 (ru) | ||
RU2016101958A (ru) | Пиразольные соединения в качестве модуляторов fshr и их применение | |
JP2013533253A5 (ru) | ||
EA201270266A1 (ru) | Гетероциклические соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160120 |